From Yahoo Finance: 2025-06-13 14:12:00

Verona Pharma plc (NASDAQ:VRNA) has been named one of the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies raised the price target for VRNA to $110, with a “Buy” rating, following strong sales growth of the COPD treatment Ohtuvayre. In the first quarter, Ohtuvayre generated $71 million in sales, up nearly 90%. Peak sales projections for VRNA range from $3 billion to $5 billion, showing significant potential for growth. Some believe VRNA could reach $1 billion in sales by 2028, driven by its safety profile and underserved market for COPD treatment. Despite VRNA’s potential, other AI stocks may offer greater upside potential.



Read more at Yahoo Finance: Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch